Senti Biosciences Plans Tax-Free Holding Company Reorganization
TipRanks (Wed, 1-Apr 5:34 PM ET)
Globe Newswire (Wed, 1-Apr 8:45 AM ET)
Globe Newswire (Fri, 27-Mar 8:00 AM ET)
Globe Newswire (Mon, 23-Mar 9:00 AM ET)
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Globe Newswire (Tue, 3-Mar 9:05 AM ET)
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Globe Newswire (Tue, 24-Feb 9:15 AM ET)
Globe Newswire (Fri, 20-Feb 8:50 AM ET)
Globe Newswire (Wed, 11-Feb 8:35 AM ET)
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
Globe Newswire (Tue, 3-Feb 9:00 AM ET)
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Senti Biosciences trades on the NASDAQ stock market under the symbol SNTI.
As of April 2, 2026, SNTI stock price climbed to $0.86 with 64,452 million shares trading.
SNTI has a beta of 1.44, meaning it tends to be more sensitive to market movements. SNTI has a correlation of 0.06 to the broad based SPY ETF.
SNTI has a market cap of $26.67 million. This is considered a Sub-Micro Cap stock.
Last quarter Senti Biosciences reported $22,000 in Revenue and -$.53 earnings per share. This fell short of revenue expectation by $-478,000 and missed earnings estimates by -$.07.
In the last 3 years, SNTI traded as high as $16.94 and as low as $.77.
The top ETF exchange traded funds that SNTI belongs to (by Net Assets): VTI, VXF, IWC.
SNTI has underperformed the market in the last year with a price return of -73.3% while the SPY ETF gained +17.5%. SNTI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.2% and -4.9%, respectively, while the SPY returned -3.7% and -0.1%, respectively.
SNTI support price is $.80 and resistance is $.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNTI shares will trade within this expected range on the day.
